ArticleAME case reports2026
Staged transition from veno-arterial extracorporeal membrane oxygenation to left ventricular assist device using Extra-VAD in acute myocardial infarction cardiogenic shock: a case report of individualized management.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myocardial infarction (AMI) and cardiogenic shock (CS) in patients requiring veno-arterial extracorporeal membrane oxygenation (V-A ECMO) are life-threatening, with extremely high mortality and complication rates due to hemodynamic instability and multiple organ dysfunction. A durable left ventricular assist device (LVAD) is a viable therapeutic option for these patients with severely impaired cardiac function who have failed attempts to wean from V-A ECMO. However, accurate assessment of right heart function during V-A ECMO and the complication rates associated with prolonged V-A ECMO support limit its long-term use. The MoyoAssist Case Description: A 58-year-old male was diagnosed with AMI accompanied by CS requiring V-A ECMO and intra-aortic balloon pump (IABP) assistance. Due to low left ventricular ejection fraction (LVEF) and difficulty in weaning from V-A ECMO, the patient was transferred to our hospital via ambulance on day 14 after V-A ECMO assistance. Despite optimization of medical therapy for heart failure following admission, ventricular function remained poor. Moreover, the IABP was removed on day 18 because of abdominal pain and marked leukocytosis. Over time, the sequelae of extended V-A ECMO support became apparent, characterized by systemic inflammation, impaired multi-organ perfusion, and the emergence of typical device-related complications. In response to this deterioration, an interventional Extra-VAD was implanted on day 19. Following several days of Extra-VAD support, despite improvement in general condition and organ function, left ventricular function remained poor. Thus, on day 25, our team proceeded with definitive LVAD implantation and removal of the Extra-VAD. The patient was discharged with LVAD support on postoperative day 38 and transitioned to outpatient follow-up care. Conclusions: This case demonstrates a staged bridging strategy from V‑A ECMO and Extra‑VAD to definitive LVAD therapy for acute circulatory failure. This approach achieves hemodynamic stability and organ protection in critically ill patients with shock and multi‑organ injury, provides a crucial time window for subsequent treatment, and underscores the value of a staged, minimally invasive, and individualized mechanical circulatory support strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.